A biologics license application (BLA) has been submitted to the FDA for etentamig (ABBV-383), an investigational BCMA x CD3 ...

ADCs improved on chemotherapy-based regimens in PD-L1–negative and EGFR-mutated NSCLC, while chemotherapy plus pembrolizumab ...

Bhavana Pothuri, MD, discusses phase 3 TroFuse-005 data from ESMO, where sac-TMT improved PFS and OS vs chemotherapy in endometrial cancer.

Rotow, MD, explains how RNA-based next-generation sequencing (NGS) fits into testing for newly diagnosed advanced nonsquamous non-small cell lung cancer (NSCLC) in a discussion moderated by Matthew A.

The investigational menin inhibitor is being evaluated in a registrational phase 2 trial for patients with relapsed or ...

Overall, Lorusso characterizes the TroFuse-005 findings as convincing, citing the magnitude of benefit across key clinical ...

Emiltatug ledadotin is a B7-H4–directed antibody-drug conjugate that has shown antitumor activity in adenoid cystic carcinoma and other solid tumors. FDA approves an all-oral treatment for newly ...

1. FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer ...

Tamim Niazi, MDCM, discusses key findings from the phase 3 DASL-HiCaP study presented at the 2026 ESMO Congress.

Olomorasib is an investigational, selective KRAS G12C inhibitor with central nervous system activity. The phase 3 SUNRAY-01 ...

John Bridgewater, BA, MBBS, MRCP, PHD, discusses the potential impact of the phase 3 HARMONi-GI1 trial on treating advanced ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...